North America Non-Invasive Cancer Diagnostics Market

North America Non-Invasive Cancer Diagnostics Market Size (2024 to 2029)

As Per the Report, the North America Non-Invasive Cancer Diagnostics Market Size was valued at USD 48.07 Billion in 2024 and estimated to grow at a CAGR of 6.61%, to reach USD 66.20  billion by 2029 during the forecast period 2024 to 2029.

North America Non-Invasive Cancer Diagnostics Market Drivers

According to the American Cancer Society, in the U.S., more than 1,660,290 cancer cases were diagnosed in 2015. Growing occurrences of cancer cases are expected to flourish the market growth. Increasing prominence over conventional methods and a growing number of breast cancer cases are leveraging the market demand. Escalating government initiatives for developing healthcare infrastructure in developing countries is mounting the market growth. Non-invasive diagnosis is having quick demand for mounting the growth of the market. Expansion of consciousness in people regarding different types of cancer and the associated treatments is gaining traction towards the market demand.

Enlarging government funds and investments towards research and development activities for the early diagnosis of the disease is gaining market growth. Increasing advancements in technology for cancer detection are augmenting market demand. Growing occurrences of cancer cases, increasing prominence over conventional methods and a growing number of breast cancer cases are some of the significant factors pulling off the market growth.

North America Non-Invasive Cancer Diagnostics Market Restrains

The cost associated with the diagnosis and treatment procedures regarding cancer is very expensive, which is unaffordable is negatively impacting the market growth. Strict government rules and regulations for the approval of devices and diagnosis is restricting the market demand.

This research report on the North America Non-Invasive Cancer Diagnostics Market has been segmented and sub-segmented into the following categories

By Therapeutics:

• Blood cancer
• Breast Cancer
• Lung Cancer
• Solid tumors

By Techniques:

• Immunochemistry
• Clinical Chemistry
• Molecular Diagnostics

By Country:

• US
• Canada
• Rest of North America

Regionally, North America is leading the market with the largest shares in the market. The market size is expected to grow with the highest CAGR during the forecast period 2024-2029. Factors like increasing the patient population suffering from different types of cancer and rising disposable income.

A surge in the introduction of new devices used for diagnosis purposes and growing awareness among the people regarding the symptoms, diagnosis, and treatments are expanding the growth of the non-invasive cancer diagnostics market. Quick advancements in the growth of the technology and invention of the devices are mounting the market demand. Quick product launches, increasing aging population, and rising obesity population are likely to propel the market growth.

The United States Non-Invasive Cancer Diagnostics Market is leading the market with the highest share. The growing number of mergers and acquisitions is escalating market demand. The upsurge in technology advancements by the key players in manufacturing efficient devices and initiatives taken by the government for cancer screening in the early stages are escalating the market growth. The American Cancer Society has made some rules for the detection of cancer, providing different plans at different stages. Women aged between 40 and 44 have to undergo breast cancer screening every year.

The Canada Non-Invasive Cancer Diagnostics Market is next to the U.S in leading the non-invasive cancer diagnostics market. Growing healthcare expenses, rising research studies in the oncology field, and escalation demand for non-invasive cancer diagnosis technologies are progressing the market demand.

Promising Companies dominating the North America Non-Invasive Cancer Diagnostics Market Profiled in the Report are Precision Therapeutics, Laboratory Corporation of America Holdings (LabCorp), BIOVIEW Inc.,   Affymetrix Inc., AVIVA Biosciences Corporation, A&G Pharmaceutical, Quest Diagnostics Incorporated Cancer Genetics Inc., Digene Corporation, and Gen-Probe Incorporated.